Rallybio (RLYB) Free Cash Flow (2020 - 2026)
Rallybio (RLYB) posted Free Cash Flow of -$8.0 million for Q1 2026, down 70.51% sequentially from -$4.7 million in Q4 2025, and up 21.82% YoY from -$6.5 million in Q1 2025.
Rallybio (RLYB) Free Cash Flow (2020 - 2026) Analysis & Trends
Rallybio has reported Free Cash Flow for 7 years, with the latest figure at -$8.0 million in Q1 2026.
- Quarterly Free Cash Flow rose 21.82% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (up 37.35% YoY) and the FY2025 annual result came in at -$29.8 million, up 39.51% from the prior year.
- Free Cash Flow slipped to -$8.0 million in Q1 2026 per RLYB's latest filing, from -$4.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$4.7 million in Q4 2025 and troughed at -$18.8 million in Q1 2023.
- A 5-year average of -$12.0 million and a median of -$13.4 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 52.83% in 2022, then surged 52.56% in 2025.
- Over 5 years, Free Cash Flow stood at -$15.3 million in 2022, then climbed by 23.98% to -$11.6 million in 2023, then grew by 15.31% to -$9.9 million in 2024, then jumped by 52.56% to -$4.7 million in 2025, then slumped by 70.51% to -$8.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$8.0 million, -$4.7 million, and -$6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 45.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.92 Mn |
| Jun 30, 2026 | 45.92 Mn |
| Mar 31, 2026 | -7.98 Mn |
| Mar 31, 2026 | -7.98 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Sep 30, 2025 | -6.55 Mn |
| Sep 30, 2025 | -6.55 Mn |
| Jun 30, 2025 | -8.38 Mn |
| Jun 30, 2025 | -8.38 Mn |
| Mar 31, 2025 | -10.21 Mn |
| Mar 31, 2025 | -10.21 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -13.55 Mn |
| Sep 30, 2024 | -13.55 Mn |
| Jun 30, 2024 | -10.42 Mn |
| Jun 30, 2024 | -10.42 Mn |
| Mar 31, 2024 | -15.46 Mn |
| Mar 31, 2024 | -15.46 Mn |